Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antiviral vaccines - Profectus BioSciences

Drug Profile

Research programme: antiviral vaccines - Profectus BioSciences

Alternative Names: Chikungunya virus vaccine - Profectus; filovirus MCM - Profectus; HCV vaccine - Profectus BioSciences; HPV vaccine - Profectus BioSciences; HSV vaccine - Profectus BioSciences; Preventative HIV rVSV vaccine - Profectus; rVSV-Ebola vaccine - Profectus; rVSV-QUAD; rVSV-Sudan; rVSV-VHF; rVSVN4CT1 Z Ebola; VesiculoVax rVSV-vectored Ebola/Marburg vaccine; VesiculoVax™-EEEV; VesiculoVax™-VEEV; Z EboV rVSVN4CT1

Latest Information Update: 28 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Profectus Biosciences
  • Developer Emergent BioSolutions; Profectus Biosciences; University of Texas Medical Branch
  • Class AIDS vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lassa fever
  • No development reported Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Marburg virus disease; Venezuelan equine encephalomyelitis; Viral infections; Zika virus infection

Most Recent Events

  • 28 May 2021 No recent reports of development identified for preclinical development in Chikungunya-virus-infections(Prevention) in USA (Parenteral, Injection)
  • 28 May 2021 No recent reports of development identified for preclinical development in Eastern-equine-encephalomyelitis(Prevention) in USA (Parenteral)
  • 28 May 2021 No recent reports of development identified for preclinical development in Ebola-virus-infections(Prevention) in USA (IM, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top